News | Rhee Lab

Weill Cornell Advances TB Research with Support from NIH

March 20, 2022

Tuberculosis (TB) is a wily old killer, one of the deadliest infectious diseases in history and one of the few that naturally infects only humans. Researchers at Weill Cornell Medicine have been pursuing treatments for tuberculosis caused by Mycobacterium tuberculosis (Mtb) since the 1950s, and the program continues to excel at explaining TB’s mysteries and pushing toward more effective therapies....

Commentary: Multisector Research Collaborative Aims to Advance Tuberculosis Treatment

March 20, 2022

A better understanding of the biology of tuberculosis (TB) infection and improved drug combinations for the disease are two areas of research in which the TB Drug Accelerator (TBDA) has made strides since its inception a decade ago, according to a commentary whose authors include three Weill Cornell Medicine investigators and an investigator at Cornell University’s Ithaca campus who participate in the collaborative network....

Scientists Discover Potential New Target for Future Tuberculosis Drugs

March 20, 2022

A team of scientists from Weill Cornell Medicine and Texas A&M University has identified a tuberculosis (TB) protein that future drugs might be able to target, with minimal side-effects compared to current treatments—potentially a critical discovery given the global public health crisis of drug-resistant TB... Read More

1 of 4
next ›